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Results from the Women’s Health Initiative (WHI) trial support findings from observational studies that oestrogen–progestin therapy
(EPT) use is associated with an increase in breast cancer risk. We conducted a meta-analysis using EPT-specific results from the
Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) pooled analysis and studies published since that report to
obtain an overview of EPT use and breast cancer risk. We also assessed risk by histologic subtype of breast cancer, by schedule of the
progestin component of EPT, and by recency of use. We estimate that overall, EPT results in a 7.6% increase in breast cancer risk per
year of use. The risk was statistically significantly lower in US studies than in European studies – 5.2 vs 7.9%. There was a significantly
higher risk for continuous-combined than for sequential EPT use in Scandinavian studies where much higher total doses of progestin
were used in continuous-combined than in sequential EPT. We observed no overall difference in risk for lobular vs ductal carcinoma
but did observe a slightly higher risk for current vs past EPT use.
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The Collaborative Group on Hormonal Factors in Breast Cancer
(CGHFBC) (1997) pooled data from 51 epidemiologic studies to
obtain an overall estimate of breast cancer risk associated with
menopausal hormone therapy (HT) use. The risk estimate for
oestrogen therapy (ET) use was based on large numbers of cases
and controls, but the oestrogen–progestin therapy (EPT) result
was not. Since then, a number of statistically powerful studies have
evaluated EPT in relation to breast cancer risk. Some of these
further evaluated differences in risk by schedule of progestin
administration, that is, sequential vs continuous-combined use
(Magnusson et al, 1999; Ross et al, 2000; Schairer et al, 2000;
Newcomb et al, 2002; Porch et al, 2002; Weiss et al, 2002; Million
Women Study, 2003; Olsson et al, 2003; Stahlberg et al, 2004), and
in relation to histologic subtype of breast cancer (Schairer et al,
2000; Daling et al, 2002; Newcomb et al, 2002; Newcomer et al,
2003; Ursin et al, 2002; Weiss et al, 2002).
We conducted a meta-analysis of the results reported by the
CGHFBC and studies published since that overview through March
2004 to provide a more precise estimate of the risk from EPT and
how it is affected by schedule of progestin administration and
histologic subtype.
MATERIALS AND METHODS
We used the Medline database to compile a list of studies
subsequent to the CGHFBC report investigating the relationship
between EPT and incident breast cancer risk using the Medical
Subject Headings (MeSH): postmenopausal, oestrogen progestin
therapy (or combined therapy), and breast cancer. For this
analysis we did not include studies that presented results only
for overall HT, nor did we include studies that only evaluated ET
use, nor studies only evaluating breast cancer mortality. A total of
22 studies were identified for possible inclusion (Persson et al,
1996, 1997, 1999; Magnusson et al, 1999; Li et al, 2000, 2002, 2003;
Moorman et al, 2000; Rockhill et al, 2000; Ross et al, 2000; Schairer
et al, 2000; Chen et al, 2002; Daling et al, 2002; Kirsh and Kreiger,
2002; Newcomb et al, 2002; Newcomer et al, 2003; Porch et al,
2002; Ursin et al, 2002; Weiss et al, 2002; Chlebowski et al, 2003;
Jernstrom et al, 2003; Million Women Study, 2003; Olsson et al,
2003; Stahlberg et al, 2004). As age at menopause is a critical factor
in assessing HT use and breast cancer risk (Pike et al, 1998), we
excluded those studies that did not adjust for age at menopause:
this criterion excluded five studies (Persson et al, 1997; Moorman
et al, 2000; Chen et al, 2002; Li et al, 2002, 2003). We also excluded
three studies that did not have information on risk by duration of
EPT use (Persson et al, 1996; Li et al, 2000; Newcomer et al, 2003),
and the study of Olsson et al (2003) for reasons described in the
Discussion section below. We further excluded two studies since
the results were based on the same data incorporated into the
CGHFBC report (Persson et al, 1999; Rockhill et al, 2000), and the
study of Jernstrom et al (2003), because it only provided results for
continuous-combined EPT use, and the reason for this was the
greater observed effect with such use than with sequential use.
Therefore, the results from 10 recent studies and from the
CGHFBC pooled analysis were used to obtain an overall
assessment of EPT and breast cancer risk (CGHFBC, 1997;
Magnusson et al, 1999; Ross et al, 2000; Schairer et al, 2000;
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yKirsh and Kreiger, 2002; Newcomb et al, 2002; Porch et al, 2002;
Weiss et al, 2002; Chlebowski et al, 2003; Stahlberg et al, 2004).
In a second analysis, breast cancer risk by histologic subtype
(lobular vs ductal) was evaluated in relation to EPT use. Four of the
10 studies had information on histology (Schairer et al, 2000;
Daling et al, 2002; Newcomb et al, 2002; Ursin et al, 2002);
Ursin et al (2002) used data from the study of Ross et al (2000)
and Daling et al (2002) from the study of Weiss et al (2002).
No information was available by histologic subtype from the
CGHFBC report.
In a third analysis, we assessed breast cancer risk by progestin
schedule (sequential, i.e. oestrogen given alone during the first part
of a monthly cycle followed by oestrogen combined with a
progestin for the remainder of the cycle with possibly a short
hormone-free interval, vs continuous-combined, i.e. oestrogen and
progestin always administered together during a cycle). No
information was available by progestin schedule from the CGHFBC
report on EPT use and breast cancer risk. Seven of the 10 studies
had data subdivided by progestin schedule of EPT use (Magnusson
et al, 1999; Ross et al, 2000; Newcomb et al, 2002; Porch et al, 2002;
Weiss et al, 2002; Million Women Study, 2003; Stahlberg et al,
2004). However, two of these seven studies did not assess duration
of use in relation to schedule and were omitted from this analysis
(Newcomb et al, 2002; Porch et al, 2002).
As so few studies provided information on past HT use, we were
limited in our ability to assess the difference in risk by recency of
use. Of the 11 studies included in the overall analysis, four studies
presented results comparing risk for past vs current HT use
(Magnusson et al, 1999; Newcomb et al, 2002; Weiss et al, 2002;
Million Women Study, 2003). Of these, three studies assessed risk
by duration of past and current HT use and were included in the
analysis (Magnusson et al, 1999; Weiss et al, 2002; Million Women
Study, 2003), but only the study by Weiss et al (2002) reported risk
for EPT use exclusively; the other two studies (Magnusson et al,
1999; Million Women Study, 2003) reported risk by past combined
EPT and ET use.
Log odds ratios (LORs) per year of use (LOR1) and 95%
confidence intervals (CI) were calculated for each study using the
meta-analytic methods described by Greenland (Rothman and
Greenland, 1998). The model fitted is log-linear in duration of EPT.
(The hazard ratios calculated for the prospective and randomised
trial studies closely approximate ORs and we refer to both as ORs
in this paper.) For all analyses, the most fully adjusted multivariate
odds ratios were used. The fixed-effects and random effects summary
LOR1s were calculated by standard methods (DerSimonian and
Laird, 1986; Fleiss, 1986). For all tables, we only present the fixed-
effects LOR1s and provide two-sided P-values for heterogeneity as
Phet. All analyses including funnel plots (Begg and Mazumdar,
1994; Egger et al, 1997) were conducted using the meta and
metabias commands in STATA (Stata Corporation, College
Station, TX, USA).
The Women’s Health Initiative (WHI) trial (Chlebowski et al,
2003) found, based on an intent-to-treat analysis, an average odds
ratio (AOR) of invasive breast cancer of 1.24 for EPT use after an
average of 5.6 years of follow-up. To convert this 1.24 figure into
an OR1, we proceeded as follows: writing the instantaneous OR at
the end of d years of use as ORd, then the AOR up to the end of
year t, AORt, is the integral of the ORd’s with d taking all values
from 0 through t divided by the cumulative standardised risk in
women not exposed to EPT, that is, t. This can be shown to result
in the following equation:
AOR5:6¼ 1:24 ¼½ ð OR
5:6
1   1Þ=lnðOR1Þ =5:6
Solving this equation gives OR1¼1.080.
For cohort studies, the true duration of EPT use is under-
estimated in current hormone users. This is because EPT use is
assessed at baseline but continues for an unknown proportion of
individuals for at least some further period until censoring time.
Therefore, an additional duration of use should be added for
current hormone users in the cohort studies considered (CGHFBC,
1997; Schairer et al, 2000; Porch et al, 2002; Million Women Study,
2003; Stahlberg et al, 2004). For example, in the cohort study of
Porch et al (2002), they reported OR’s of 1.11 and 1.76 for o5 and
X5 years of EPT use. We considered these categories as referring
to 2.5 and 7.5 years of EPT use. Using these duration figures, we
estimated OR1 as 1.079. But the ORs of 1.11 and 1.76 do not relate
to 2.5 and 7.5 years of use, but to this amount of use plus the mean
duration of use after recruitment to the study until the end of
follow-up. The mean length of follow-up in this study was 5.9 years
and assuming that current users of EPT remained users during
follow-up, this changes the values to be used in estimating OR1
from 2.5 and 7.5 years to 5.45 (2.5 plus the midpoint of the average
follow-up, i.e. 5.9/2 or the average exposure during follow-up) and
10.45 (7.5 þ 5.9/2) years, respectively. This changes our estimate
of OR1 from 1.079 to 1.052, a 34% decline in our estimate of excess
risk. This is, of course, a slight exaggeration of the change since
some current users at baseline will stop use during follow-up. For
all cohort studies included in the analysis, we calculated risk per
year of use based on this conservative method. We applied this
method to all prospective studies reporting risk for current EPT
use except for the study by Schairer et al (2000), in which this
adjustment had already been applied.
Risk estimates reported in the study by Magnusson et al (1999)
were converted to risks per year of use since the OR1s reported in
the study excluded never users of EPT. This was done in order for
these estimates to be comparable to the relative risks reported in
the other studies.
RESULTS
The studies included in at least one of the three analyses conducted
to evaluate EPT and breast cancer risk are given in Appendix A. A
summary table of the general characteristics and overall findings
for each study are presented in Appendix B. As is apparent in the
summary table, the effect of EPT use by duration of use in these
various studies was evaluated in a wide variety of ways with
categorical cutpoints, as well as per year of use.
EPT and breast cancer risk
The overall summary of the studies included in this meta-analysis
(all histologic subtypes combined) showed a weighted average OR1
of 1.076. (95% confidence interval (CI)¼1.070, 1.082) for EPT use,
with some evidence of heterogeneity, Phet¼0.074 (Table 1,
Figure 1). A funnel plot showed no evidence of publication bias.
The OR1 for the US studies was 1.052 (95% CI¼1.036, 1.068); for
the European studies was 1.079 (95% CI¼1.073, 1.085); and for the
Scandinavian studies was 1.089 (95% CI¼1.065, 1.114): the
difference between the US studies and the European studies was
highly statistically significant (P¼0.002) (Table 1).
EPT by sequential vs continuous-combined schedules and
breast cancer risk
Sequential EPT use was associated with a lower OR1 than
continuous-combined EPT use (Table 2). The best estimate of
the overall difference between the OR1s was  0.015 (95%
CI¼ 0.030, 0.000), Pdiff¼0.054. The most obvious difference
between the continuous-combined and sequential schedules was
seen in the two Scandinavian studies (Magnusson et al, 1999;
Stahlberg et al, 2004) in which the difference in OR1s was  0.065
(95% CI¼ 0.115,  0.015), Pdiff¼0.010. In the remaining studies
the average OR1 difference was  0.010 (95% CI¼ 0.026, 0.006),
Pdiff¼0.23; this figure essentially reflects the Million Women Study
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two studies (Ross et al, 2000; Weiss et al, 2002) had differences of
 0.056 and 0.050.
EPT and lobular vs ductal breast cancer risk
Two of the four studies evaluating the difference in risk between
lobular and ductal breast carcinoma found no difference by
histology while the other two studies observed a slightly increased
risk for lobular carcinoma (Table 3). The overall difference in risk
(at one year) by histologic subtype was 0.019 (95% CI¼ 0.033,
0.071), Pdiff¼0.47.
Current/recent use vs total lifetime use and breast
cancer risk
Only three studies (Magnusson et al, 1999; Weiss et al, 2002;
Million Women Study, 2003) reported results comparing risk for
past vs current HT use. Pooled estimates for these three studies
showed that the difference in OR1s was  0.067 (95% CI¼ 0.081,
 0.053), Pdiffo0.001 (Table 4). In the study by Weiss et al (2002),
the only study to report risk separately for past and current EPT
use, the difference was  0.100 ( 0.166,  0.034), Pdiff¼0.003.
As another way to assess potential difference in risk by recency
of use, we calculated pooled estimates for those studies reporting
relative risks among current/and or recent EPT use (CGHFBC,
1997; Schairer et al, 2000; Porch et al, 2002; Chlebowski et al, 2003;
Million Women Study, 2003; Stahlberg et al, 2004) and compared
them to pooled estimates for the studies reporting risk for lifetime
EPT use (Magnusson et al, 1999; Ross et al, 2000; Kirsh and
Kreiger, 2002; Newcomb et al, 2002; Weiss et al, 2002). The pooled
estimate (data not shown) for the studies assessing current/recent
use was slightly higher (OR1¼1.077, 95% CI¼1.071, 1.083) than
the pooled estimate for studies reporting lifetime EPT use
(OR1¼1.053, 95% CI¼1.034, 1.072), and this difference was
statistically significant, Pdiff¼0.019. This difference remained
significant even after excluding the Scandinavian studies (Mag-
nusson et al, 1999; Stahlberg et al, 2004): the weighted average OR1
for current/recent use was 1.076 (95% CI¼1.070, 1.082) and 1.049
(95% CI¼1.028, 1.070) for lifetime use, Pdiff¼0.017.
DISCUSSION
The literature evaluating EPT and breast cancer risk is generally
very consistent; all studies reported an increased risk of breast
cancer with increasing duration of EPT use. The overall evidence
showed a statistically significant increased risk of 7.6% per year of
use. The risk was statistically significantly lower in US studies than
in European studies – 5.2 vs 7.9%.
The US figure should probably be increased slightly since the
results we used for the WHI trial (Chlebowski et al, 2003) are
almost certainly an underestimate of the true effect in that trial. We
used the result obtained from their intent-to-treat analysis. The
results from their drug-as-taken analysis was double that obtained
from the intent-to-treat analysis. The WHI trial result has,
however, only a small effect on the overall risk for US studies as
it is associated with a wide CI. The results of the Scandinavian
study of Stahlberg et al (2004) are likewise likely to be an
underestimate, although to a smaller extent than with the
WHI, as the authors only adjusted for age at menopause as o55
and X55 years.
The overall within-study difference between sequential vs
continuous-combined EPT was  0.015 (95% CI¼ 0.030, 0.000),
Pdiff¼0.054. This difference was due to the two Scandinavian
studies (Magnusson et al, 1999; Stahlberg et al, 2004) where the
risk was  0.065 (95% CI¼ 0.115,  0.015), Pdiff¼0.010. This
difference was also supported by the results of the Scandinavian
study reported by Jernstrom et al (2003), which we excluded
earlier since the authors only presented results for continuous-
combined EPT use; the authors reported their results in this
manner because of the greater observed effect for continuous-
combined than for sequential EPT use.
In the US, the most common form of sequential EPT provides
5–10mg of medroxyprogesterone acetate (MPA) per day for 10
days per 28-day cycle, whereas subjects assigned to receive
continuous-combined EPT are typically given 2.5mg of MPA
every day. The total doses for sequential and continuous-combined
Table 1 Odds ratios per year of use (OR1s) of oestrogen–progestin
therapy and breast cancer risk
Study Case users OR1 (95% CI)
Randomised trial
WHI
1 (2003)
a 199 1.080 (1.004, 1.167)
Prospective studies
Stahlberg
2 (2004)
a,b 95 1.097 (1.068, 1.127)
MWS
3 (2003)
a,c 1891 1.077 (1.071, 1.084)
Porch
4 (2002)
a,b,c 164 1.052 (1.022, 1.084)
Schairer
5 (2000)
a,d 75 1.060 (0.998, 1.150)
Case–control studies
Kirsh
6 (2002)
b,c 43 1.15 (1.01, 1.33)
Newcomb
7 (2002)
c 215 1.04 (1.01, 1.08)
Weiss
8 (2002) 195 1.065 (1.019, 1.114)
Ross
9 (2000)
b 425 1.044 (1.014, 1.077)
Magnusson
10 (1999)
b 399 1.104 (1.073, 1.136)
Pooled studies
CGHFBC
11 (1997)
a,e 194 1.058 (0.996, 1.124)
Summary Pooled estimate
All studies 1.076 (1.070, 1.082) Phet¼0.074
US studies
1, 4 9,11 1.052 (1.036, 1.068) Phet¼0.87
European studies
2,3,10 1.079 (1.073, 1.085) Phet¼0.12
Scandinavian studies
2,10 1.089 (1.065, 1.114) Phet¼0.32
Abbreviations: CI¼confidence interval; OR¼odds ratio; WHI¼Women’s Health
Initiative; MWS¼Million Women Study; CGHFBC¼Collaborative Group on
Hormonal Risk Factors in Breast Cancer.
aRisk is based on current and/or recent
use rather than total use.
bResults included (or did not specifically exclude) in situ
breast cancer cases.
cResults included (or did not specifically exclude) women with
unknown age at menopause due to simple hysterectomy.
dCalculated number of
cases for women with known age at menopause: 80% of the total number of cases
(n¼93).
eIncludes mostly US studies.
RR
0.9 1 1.1 1.2 1.3
Combined
CGHFBC
Magnusson
Ross
Weiss
Newcomb
Kirsh
Schairer
Porch
MWS
Stahlberg
WHI
Figure 1 Studies included in overall analysis of EPT and risk of breast
cancer: odds ratios with 95% CIs per year of use.
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per cycle. In contrast, in Scandinavia, the total dose of the
progestin is much higher with continuous-combined than with
sequential EPT, at least for two commonly prescribed regimens
using norethisterone acetate (NETA). In these regimens, the same
daily dose of NETA, 1mg, is used with both the sequential and the
continuous-combined EPT, so that the total NETA dose per cycle is
roughly 10 and 28mg respectively. The situation in the UK is more
like that in the US, with the continuous-combined regimens using
lower daily progestin doses than that used in the sequential
regimens, so that total progestin doses are not that different. This
would be in agreement with the results found by the Million
Women Study (2003).
Some of the difference in the risks found between the US studies
and the European studies are due to the higher risks found with
sequential regimens in Scandinavia and likely due to higher total
doses of progestin (as described above). The remainder may be
due to the much greater use of NETA and norgestrel in Europe.
Based on its effects in the endometrium (Dickey and Stone, 1976;
Back et al, 1981; Stanczyk, 2002), the progestin dose of NETA as
commonly prescribed is possibly 1.5–2.0 times the effective dose
of progestin used in the US. There is also the possibility that the
different types and doses of oestrogen used have different effects.
Finally, some of the differences in risk may be due to a greater
relative effect of HT use on breast cancer risk among leaner
women. The women in the US studies in this meta-analysis
are in general heavier than the women in the European
studies, consistent with overall population demographics. In this
meta-analysis we did not assess differences in risk by weight as
only two studies evaluated risk with duration of EPT use (Schairer
et al, 2000; Ursin et al, 2002) and the study of Ursin et al with
much larger numbers found no differential effect of BMI; the
others only gave results with duration of HT use (Magnusson
et al, 1999), or with ever HT or EPT use (CGHFBC, 1997; Newcomb
et al, 2002; Ursin et al, 2002; Weiss et al, 2002; Million Women
Study, 2003).
Table 2 Odds ratios per year of use (OR1s) of oestrogen–progestin therapy and breast cancer risk by progestin schedule
Sequential Continuous
Study Case users OR1 (95% CI) Case users OR1 (95% CI) Difference
Prospective studies
Stahlberg et al
2 (2004)
a,b 29 1.063 (1.024, 1.103) 20 1.137 (1.093, 1.182)  0.074 ( 0.134,  0.014)
MWS
3 (2003)
a,c 1181 1.093 (1.083, 1.103) 631 1.106 (1.093, 1.120)  0.013 ( 0.030, 0.004)
Case–control studies
Weiss
8 (2002) 78 1.031 (0.966, 1.100) 166 1.087 (1.020, 1.159)  0.056 ( 0.153, 0.041)
Ross
9 (2000)
b 320 1.067 (1.025, 1.109) 105 1.017 (0.975, 1.062) 0.050 ( 0.010, 0.110)
Magnusson
10 (1999)
b 102 1.088 (1.022, 1.158) 135 1.132 (1.072, 1.197)  0.044 ( 0.136, 0.048)
Summary Pooled estimate Pooled estimate Pooled estimate
All studies 1.089 (1.080, 1.098) 1.103 (1.092, 1.115)  0.015 ( 0.030, 0.000)
Phet¼0.20 Phet¼0.002 Pdiff¼0.054
US studies
8,9 1.057 (1.022, 1.093) 1.038 (1.002, 1.076) +0.020 ( 0.031, 0.071)
Phet¼0.38 Phet¼0.090 Pdiff¼0.44
European studies
2,3,10 1.091 (1.082, 1.101) 1.110 (1.098, 1.122)  0.018 ( 0.034,  0.002)
Phet¼0.36 Phet¼0.33 Pdiff¼0.024
Scandinavian studies
2,10 1.070 (1.036, 1.104) 1.135 (1.100, 1.172)  0.065 ( 0.115,  0.015)
Phet¼0.53 Phet¼0.92 Pdiff¼0.010
Abbreviations: CI¼confidence interval; OR¼odds ratio; WHI¼Women’s Health Initiative; MWS¼Million Women Study; CGHFBC¼Collaborative Group on Hormonal Risk
Factors in Breast Cancer.
aRisk was based on current and/or recent use rather than total use.
bRisk included (or did not specifically exclude) in situ breast cancer cases.
cResults
included (or did not specifically exclude) women with unknown age at menopause due to simple hysterectomy.
Table 3 Odds ratios per year of use (OR1s) of oestrogen–progestin therapy and breast cancer risk by histologic subtype
Lobular Ductal
Study Case users OR1 (95%CI) Case users OR1 (95%CI) Difference
Prospective studies
Schairer
5 (2000)
a,b,c 33 1.17 (1.02, 1.41) 26 1.17 (1.02, 1.41) 0.000 ( 0.276, 0.276)
Case–control studies
Daling
13 (2002) 44 1.096 (1.007, 1.193) 209 1.039 (0.99, 1.089) 0.057 ( 0.048, 0.162)
Newcomb
7 (2002)
a 32 1.04 (0.97, 1.11) 208 1.04 (1.00, 1.08) 0.000 ( 0.109, 0.109)
Ursin
14 (2002) 46 1.060 (0.996, 1.128) 291 1.049 (1.016, 1.084) 0.011 ( 0.063, 0.085)
Summary Pooled estimate Pooled estimate Pooled estimate
1.067 (1.026, 1.110) 1.046 (1.023, 1.069) 0.019 ( 0.033, 0.071)
Phet¼0.53 Phet¼0.56 Pdiff¼0.47
Abbreviations: CI¼confidence interval; OR¼odds ratio; WHI¼Women’s Health Initiative; MWS¼Million Women Study; CGHFBC¼Collaborative Group on Hormonal Risk
Factors in Breast Cancer.
aResults included (or did not specifically exclude) women with unknown age at menopause due to simple hysterectomy.
bRisk was based on current
and/or recent use rather than total use.
cRisk among lean women, lobular/ductal vs ductal only, results included (or did not specifically exclude) in situ breast cancer.
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than for ductal carcinoma; the OR1 difference was 0.019, but this
was not statistically significant. Further data are needed on this
issue.
Schairer et al (2000) reported much higher estimates than the
other studies for both lobular (OR1¼1.17) and ductal carcinoma
(OR1¼1.17). These risks compare to their overall result (Table 1)
of an OR1 of 1.076. The explanation is that the authors only
provided results by histology among lean women, and in their
study the effect of EPT on risk was much greater in lean women.
Only the study by Weiss et al (2002) compared risk for current
vs past EPT use. Their results suggest that risk for current EPT use
is higher. The Million Women Study (2003) compared current HT
use and past EPT use, and the study by Magnusson et al (1999)
compared current and past HT use. The results from these two
studies are difficult to interpret since HT use in past users includes
proportionately more ET use. We found that recent EPT use was
associated with a higher risk than lifetime EPT use, but this
analysis was based on only a small number of studies.
The observed lower risk with past use may be due, at least in
part, to the fact that that duration of hormone use is not measured
the same in current as in past hormone users. The actual duration
of use within a duration category will tend to be longer in current
than in past users (Ettinger et al, 2003), and, in cohort studies,
duration of use is underestimated in current users since exposure
is only assessed at baseline. Nondifferential misclassification of
duration of use is also likely to be higher with past use, leading to a
greater underestimate of the risk associated with past use. Four of
the five studies reporting risk among current/recent users
addressed the possibility that a screening bias could be a possible
explanation for the observed lower risk among past users
(Schairer et al, 2000; Porch et al, 2002; Rossouw et al, 2002;
Chlebowski et al, 2003; Million Women Study, 2003). None found
any evidence of this.
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Appendix A
Studies evaluating oestrogen–progestin use and breast cancer risk.
Studies included in each analysis are represented by an ‘ ’ and
studies excluded are marked by footnotes.
Analysis 1 Analysis 2 Analysis 3 Analysis 4
Study Overall Lobular Ductal Sequential Continuous-combined Past Current
Randomised Trials
WHI
1 (2003) X
c
Prospective studies
Stahlberg
2 (2004)
a XX X
MWS
3 (2003) X X X X
e X
Porch
4 (2002) X
dd
Schairer
5 (2000) X X X
c
Case–control studies
Kirsh
6 (2002) X
Newcomb
7 (2002) X X X
dd d d
Weiss
8 (2002) X X X X X X X
Daling
13 (2002)
b
Ross
9 (2000) X X X X X
Ursin
14 (2002)
b
Magnusson
10 (1999) X X X X
e X
e
Pooled studies
CGHFBC
11 (1997) X
Abbreviations: CI¼confidence interval; OR¼odds ratio; WHI¼Women’s Health Initiative; MWS¼Million Women Study; CGHFBC¼Collaborative Group on Hormonal Risk
Factors in Breast Cancer.
aOverall risk calculated from sequential and continuous-combined use.
bResults by histologic subtype, not overall breast cancer risk (overall risk for
Daling in Weiss and for Ursin in Ross).
cOnly results for one type of progestin schedule.
dNo results given for duration of EPT use.
eRisk for ET or EPT use.
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Studies evaluating oestrogen–progestin use and breast cancer risk:
overall characteristics and main findings.
Randomised
trials Cases Population
Mean follow-up
(years)
Adjusted
variables Results
1 WHI
1 (2003) Healthy
postmenopausal
women in the
Women’s Health
Initiative Trial
199 treatment
150 placebo
8506 treatment
8102 placebo
5.6 Age, dietary
modification,
randomisation
group
1.24 (1.01, 1.54) cumulative
risk
a
Prospective
studies
Study
population
b Cases Person-years
Mean follow-up
(years)
Adjusted
variables Results
2 Stahlberg
2 (2004) Healthy
postmenopausal
women age 45+ in
the Danish Nurse
Cohort
139
c 7572
d 6.34 Age, hx of BBD,
age at meno (o55
vs X55)
Sequential
:o5yr: 1.58 (0.79, 3.17)
5–9yr: 2.47 (1.23, 4.95)
10+ yr: 2.18 (1.09, 4.33)
a
130
c 6889
d Continuous-combined:
o5 yr: 1.96 (0.72, 5.36)
5-9yr: 4.96 (2.16, 11.39)
10+ yr: 6.78 (3.41, 13.48)
a
3 MWS
3 (2003) Healthy women
e in
the UK age 50–64
as part of the
National Health
Service Breast
Screening
Programme
4785 532353
d 2.6 Age, time since
meno, parity,
AFFTP, family hx of
breast cancer, BMI,
region, deprivation
index
o1yr: 1.45 (1.19, 1.78)
1–4yr: 1.74 (1.60, 1.89)
5–9yr: 2.17 (2.03, 2.33)
X10yr: 2.31 (2.08, 2.56)
a
4075 478399
d Sequential:
o5yr: 1.77 (1.59, 1.97)
X5yr: 2.12 (1.95, 2.30)
a
3525 441751
d Continuous-combined:
o5yr: 1.57 (1.37, 1.79)
X5yr: 2.40 (2.15, 2.67)
a
1005 144697
d Past HT:
o1yr: 0.94 (0.84, 1.05)
1–4yr: 1.01 (0.92, 1.12)
5–9yr: 1.14 (1.00, 1.30)
X10yr: 1.05 (0.84, 1.30)
Current EPT: see above
results for overall analysis
4 Porch
4 (2002) Healthy female
postmenopausal
e
professionals age
45+ in the
Women’s Health
Study
310
c 71438 5.9 Age, age at meno,
meno type, age at
menarche,
nulliparity, age at
first preg,
abortions/
miscarriages,
AFFTP, OC, hx of
BBD, use of
mammo screening,
family hx breast
cancer, race, BMI,
smoking, alcohol,
exercise
o5yr: 1.11 (0.81, 1.52)
5+ yr: 1.76 (1.29, 2.39)
Ptrend¼0.0004
a
5 Schairer
5 (2000) Healthy
postmenopausal
e
women in the
Breast Cancer
Detection
Demonstration
Project
B75 (known
age meno)
B15727(known
age meno)
10.2 (over three
phases of follow-
up)
Age, edu, BMI, age
at meno, mammo
screening
1.06 (1.00, 1.15) per year of
use among known age
meno
a
33 18948 Lobular/ductal: 1.17 (1.02,
1.41) per year of use
among all women
a,f
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y26 18948 ductal: 1.17 (1.02, 1.41) per
year of use among all
women
a,f
48 18948 Sequential: (Po15 days/mo)
p4yr: 1.1 (0.8, 1.7)
44yr: 1.5 (1.0, 2.4)
among all women
a
Case–control
studies
Study
population
* Cases Controls
Adjusted
variables Results
6 Kirsh
6 (2002) Healthy
postmenopausal
e
women in Ontario,
Canada
404
c 403 Age, age at meno,
type of meno, hx of
BBD
1.15 (1.01, 1.33) per year of
use
7 Newcomb
7 (2002) Healthy
postmenopausal
e
women from
Massachusetts,
New Hampshire,
Wisconsin
4142 4418 Age at meno, type
of meno, AFFTP,
BMI, family hx
breast cancer, edu,
mammo screening
hx, recent alcohol,
hx of BBD, age at
menarche, recent
physical activity
1.04 (1.01, 1.08) per year of
use
351 4132 Lobular: 1.04 (0.97, 1.11)
per year of use
2654 4132 Ductal: 1.04 (1.00, 1.08)
per year of use
8 Weiss
8 (2002) Healthy black and
white
postmenopausal
women in Atlanta,
Detroit, Los
Angeles,
Philadelphia, Seattle
in the
Contraceptive and
Reproductive
Experiences
(CARE) Study
849 835 Age, race, study
center, type of
meno, age at meno
40t oo6 mo: 0.59 (0.40,
0.87)
6m ot oo2yr: 0.82 (0.57,
1.18)
2t oo5yr: 1.33 (0.91,
1.95)
5+ yr: 1.49 (1.05, 2.12)
672 661 Sequential: (Po25 days/
mo)
40t oo6 mo: 0.70 (0.38,
1.30)
6m ot oo2yr: 0.72 (0.42,
1.24)
2t oo5yr: 1.44 (0.79,
2.61)
5+ yr: 1.18 (0.70, 1.98)
730 696 Continuous-combined:
(PX25 days/mo)
40t oo6 mo: 0.58 (0.36,
0.94)
6m ot oo2yr: 1.11 (0.71,
1.75)
2t oo5yr: 1.38 (0.86,
2.22)
5+ yr: 1.77 (1.04, 3.01)
859 899 Past EPT
:40t oo6 mo: 0.68 (0.47,
0.99)
6m ot oo2yr: 0.76 (0.52,
1.13)
2t oo5yr: 1.24 (0.79,
1.93)
5+ yr: 0.54 (0.33, 0.88)
1174 1042 Current EPT:
40t oo6 mo: 0.53
(0.26, 1.09)
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y6m ot oo2yr: 1.11 (0.75,
1.65)
2t oo5yr: 1.28 (0.95,
1.73)
5+ yr: 1.37 (1.06, 1.77)
Daling
13 (2002) 108 835 Age, race, study
site, type of meno,
known age at meno
Lobular:
p6 mo: 0.7 (0.3, 1.5)
6 mo to 5yr: 1.3 (0.7, 2.3)
5yr+: 1.9 (1.0, 3.7)
635 835 Ductal:
p6 mo: 0.6 (0.4, 0.9)
6mo to 5yr: 1.0 (0.7, 1.3)
5yr+: 1.3 (0.9, 1.9)
9 Ross
9 (2000) Healthy
postmenopausal
women in Los
Angeles
1298
c 1108 Type of meno, age
at meno, age at
menarche, family hx
of breast cancer,
history BBD,
nulliparity, AFFTP,
OCs, BMI, alcohol
1.24 (1.07, 1.45) per 5 yr of
use
P2-sided¼0.005
1193
c 1012 Sequential: (Poentire
cycle)
1.38 (1.13, 1.68)
P2-sided¼0.0015
978
c 880 Continuous-combined:
(P¼entire cycle)
1.09 (0.88, 1.35)
P2-sided¼0.44
Ursin
14 (2002) 164 1637 Type and age at
meno, age at
menarche, family hx
breast cancer, hx of
BBD, nulliparity,
AFFTP, OCs,
weight, alcohol
Lobular:1.34 (0.98, 1.83)
per 5 yr of use
Ptrend¼0.06
1307 1637 Ductal: 1.27 (1.08, 1.50)
per 5 yr of use
Ptrend¼0.004
10 Magnusson
10
(1997)
Healthy
postmenopausal
women in Sweden
2137
c 2481 Age, parity, AFFTP,
age at meno, type
of meno, BMI,
height
1–24 mo: 1.25 (0.96, 1.63)
25–60 mo: 1.40 (1.01,
1.94)
60–120 mo: 2.43 (1.72,
3.44)
4120 mo: 2.95 (1.84,
4.72)
1841
c 2272 Sequential: (Po16 days/
mo)
1–24 mo: 1.58 (1.01, 2.46)
25–60 mo: 1.34 (0.71,
2.54)
60–120 mo: 1.89 (0.88,
4.09)
4120 mo: 2.45 (0.82,
7.30)
1874
c 2322 Continuous-combined:
(PX19 days/mo)
1–24 mo: 0.93 (0.63, 1.36)
25–60 mo: 1.26 (0.76,
2.09)
60–120 mo: 2.89 (1.66,
5.00)
4120 mo: 5.36 (1.47,
19.56)
1828
c 2302 Past HT:
(1–10 yr ago):
1–60 mo: 1.09 (0.76, 1.55)
460 mo: 1.22 (0.72, 2.08)
(4 10 yr ago):
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460 mo: 2.57 (1.28, 5.15)
2182
c 2475 Current HT (o1 yr ago):
1–60 mo: 1.52 (1.21, 1.92)
460 mo: 2.68 (2.09, 3.42)
Pooled analysis
Study
population* Cases Controls
Adjusted
variables Results
11 CGHFBC
11 (1997) Women from 22
published and two
unpublished studies
with information on
type of preparation
(EPT, ET, PT)
12611 23866 Study, age at dx or
pseudo dx, time
since meno, BMI,
parity, AFFTP
o5yr: 1.15 (s.e.¼0.19)
X5yr: 1.53 (s.e.¼0.33)
a
Abbreviations: WHI¼Women’s Health Initiative; MWS¼Million Women Study; CGHFBC¼Collaborative Group on Hormonal Risk Factors in Breast Cancer; OC¼oral
contraceptives; hx¼history; BBD¼benign breast disease; BMI¼body mass index, preg¼pregnancy; mammo¼mammography; edu¼education level; meno¼menopause;
AFFTP¼age at first full-term pregnancy; dx¼diagnosis; mo¼month(s); yr¼year(s); P¼progestin; E¼oestrogen; s.e.¼standard error.
aRisk was based on current and/or
recent use rather than total use.
bNumber of cases and number of starting population/person-years/controls for the results presented in final column.
cResults included (or did
not specifically exclude) in situ breast cancer cases.
dAuthors provided population rather than person-years.
eResults included (or did not specifically exclude) women with
unknown age at menopause due to simple hysterectomy.
fRisk among lean women.
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